Dr. Wykoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4460 Bissonnet St
Ste 200
Bellaire, TX 77401Phone+1 713-524-3434Fax+1 713-524-3220
Summary
- Board Certified by the American Board of Ophthalmology. Partner at Retina Consultants of Houston & Clinical Assistant professor at Weill Cornell Medical College, Houston Methodist Hospital. Research interests: angiogenesis & exudative retinal diseases as well as vitreoretinal surgery topics including trauma, retinal detachments, diabetic retinopthay, & macular holes. Principle investigator on numerous clinical trials including novel approaches to treating AMD, RVO and diabetic retinopathy. Member of the Macula Society, ASRS, AAO, and ARVO.
Education & Training
B Palmer Eye Institute - A B Leach EyeChief Residency, Chief Resident & Co-Director of Ocular Trauma, 2010 - 2011
University of Miami Hospital and ClinicsFellowship, Surgical Retina and Vitreous, 2009 - 2011
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2006 - 2009
Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
Harvard Medical SchoolClass of 2005
Certifications & Licensure
TX State Medical License 2011 - 2026
FL State Medical License 2009 - 2015- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Start of enrollment: 2012 Dec 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 30 citationsReal-World Trends in Intravitreal Injection Practices among American Retina Specialists.Rahul Chaturvedi, Kendall Wannamaker, Paul Riviere, Arshad M. Khanani, Charles C. Wykoff
Ophthalmology. Retina. 2019-08-01 - 7 citationsSystematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.Amin Hatamnejad, Rohan Dadak, Samantha Orr, Charles Wykoff, Netan Choudhry
BMJ Open Ophthalmology. 2023-06-01 - 321 citationsComplement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.David Liao, Federico Grossi, Delphine El Mehdi, Monica Gerber, David M. Brown
Ophthalmology. 2020-02-01
Journal Articles
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyCharles C Wykoff, Srinivas R Sadda, JAMA Ophthalmology
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLee M Jampol, Lloyd Paul Aiello, Jennifer K Sun, Szilard Kiss, Charles C Wykoff, Neil M Bressler, JAMA
Authored Content
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
Press Mentions
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 14th, 2024- Study of Alkeus' Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function ImprovementOctober 24th, 2024
- Experts Offer Guidance on Suprachoroidal Space Injections, the Newest Frontier in Retinal Drug DeliveryOctober 17th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
